三氧化二砷联合替莫唑胺与放疗治疗恶性胶质瘤的II期试验
这项I/II期试验纳入42例新诊断恶性胶质瘤患者,接受放疗60 Gy、替莫唑胺75 mg/m2每日×42天及三氧化二砷0.20 mg/kg方案。GBM患者中位无进展生存期7个月、中位总生存期17个月,间变性胶质瘤分别为75个月和未达到。三氧化二砷联合放疗与替莫唑胺可行且未增加副作用,但GBM患者总生存期较历史数据未见改善。
要点
- 42例新诊断恶性胶质瘤患者接受放疗、替莫唑胺和三氧化二砷联合治疗,方案可行。
- GBM患者中位无进展生存期7个月、中位总生存期17个月。
- 间变性胶质瘤患者中位无进展生存期75个月、中位总生存期未达到。
核心结论
- 将三氧化二砷加入放疗和替莫唑胺方案可行且未增加副作用,但三氧化二砷的加入未改善GBM患者的总生存期(相较历史数据)。
研究设计与样本
- I/II期试验,共纳入42例新诊断恶性胶质瘤患者(24例男性、18例女性),中位年龄54岁(范围24-80),中位KPS 90(范围60-100)。
- 患者接受放疗60 Gy、替莫唑胺75 mg/m2每日×42天,以及三氧化二砷0.20 mg/kg每日第1周后每周两次×5周;完成放疗后接受替莫唑胺5/28方案维持治疗最长12个月。
- 每8周进行MRI评估;放疗后替莫唑胺周期中位数为4(范围0-12)。
主要发现
- 28例为GBM,14例为间变性胶质瘤(AG);GBM中位无进展生存期7个月,AG为75个月;GBM中位总生存期17个月,AG未达到。
- 最佳疗效:完全缓解2例、部分缓解5例、疾病稳定28例、疾病进展7例。
- 可能与三氧化二砷相关的3级毒性包括QTc延长(n=1)、肝酶升高(ALT n=2、AST n=1)和胆红素升高(n=1);未出现意外不良事件。
- 42例患者中20例有组织可进行MGMT状态分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standard treatment for GBM is radiation (RT) and temozolomide (TMZ). Arsenic trioxide (ATO) is synergistic with RT based on several mechanisms of action previously identified, however not tested herein. The MTD of ATO, RT and TMZ was determined in a Phase I trial. We now present the combined Phase I/II data. Patients with newly diagnosed malignant gliomas were eligible for treatment. Patients were treated with RT (60 GY), TMZ (75 mg/m2 daily × 42 days) and ATO 0.20 mg/kg daily in week 1 then twice a week ×5 weeks, after completing RT they were treated with TMZ 5/28 for up to 12 months. MRIs were performed every 8 weeks. A total of 42 patients were enrolled in both the Phase I and II trials for this study treatment. Of the 42 enrolled patients (24 M and 18 W) the median age was 54 (24-80) and median KPS 90 (60-100). 28 patients had a GBM and 14 had anaplastic glioma (AG). All patients completed RT/TMZ/ATO and went on to maintenance TMZ. Median number of post RT cycles of TMZ was 4 (0-12). Median PFS was 7 m for GBM and 75 m for AG and median OS was 17 m for GBM and NR for AG. Best response was CR in 2, SD in 28, PR in 5 and PD in 7. There were no unexpected adverse events. Grade 3 toxicities likely attributable to ATO included prolonged Qtc (n = 1), elevated liver enzymes (n = 2 for ALT/n = 1 for AST) and elevated bilirubin (n = 1). Adding ATO to RT and TMZ is feasible with no increased side effects. The addition of arsenic did not improve overall survival in the GBM patients as compared to historic data. MGMT status was analyzed in 20 of the 42 patients where tissue was available for retrieval and MGMT testing.
引用
- Kumthekar P, Grimm S, Chandler J, et al. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. J Neurooncol. 2017. PMID: 28510787. doi:10.1007/s11060-017-2469-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。